(Charenton-le-Pont, 9 April, 2021) – Essilor will unveil the pivotal two-year clinical trial results of its Stellest™ lens – its latest breakthrough spectacle lens solution in the fight against myopia. The much-anticipated two-year results demonstrate that Essilor Stellest™ lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day1.
The presentation of this research entitled “Myopia control with spectacle lenses with aspherical lenslets: a 2-year randomized clinical trial”, will be delivered at the occasion of the Annual Meeting of the ARVO, on May 6th, 2021, by BAO Jinhua2, Associate Professor at Wenzhou Medical University, China.
Norbert Gorny, Co-Chief Operating Officer, Essilor International commented on the results, “With such impressive results, Essilor’s Stellest™ lenses will truly be a catalyst to stem myopia progression and to help children, who continue to be at risk of sight-threatening eye conditions associated with myopia. Essilor is proud to be at the forefront of myopia management and we will continue to be focused on bringing such innovative advances to move the needle on the fight against myopia.”
For further information, please refer to the press release below.
